Stereotaxis Ord - STXS STOCK NEWS

Stereotaxis (NYSE: STXS) announced a significant publication in the Journal of the American College of Cardiology, highlighting a study on robotic technology for treating chronic thromboembolic pulmonary hypertension (CTEPH). The trial, involving 50 patients, demonstrated that robotic magnetic navigation enhanced outcomes, with pulmonary vascular resistance improving significantly (p=0.001) and an 86% reduction in heart failure-related hospitalizations (p=0.049) at 12 months. This advancement in robotic technology presents a promising new therapy for pulmonary hypertension, revealing its potential beyond arrhythmias.

Stereotaxis (STXS) reported a 21% decline in second-quarter revenue, totaling $5.3 million, primarily due to a 38% drop in procedure volumes amid COVID-19 challenges. Despite this setback, the company achieved notable milestones, including the installation of the first Genesis RMN® System and advancements in its robotically-navigated ablation catheter. Operating expenses decreased 13% to $6.2 million, demonstrating prudent management. As of June 30, 2020, Stereotaxis held a cash balance of $44 million, positioning it strongly for future growth.

Stereotaxis (NYSE: STXS) and Acutus Medical have successfully conducted the first integrated cardiac ablation procedure utilizing remote TeleRobotic Support. Dr. Gery Tomassoni performed the procedure at Baptist Health in Lexington, KY, combining Stereotaxis Robotic Magnetic Navigation and Acutus' AcQMap systems. This innovative integration enhances the accuracy of arrhythmia treatment through high-resolution imaging and robotic navigation. The TeleRobotic capabilities allow real-time support from experts, improving patient care while minimizing surgical risks.

Stereotaxis (STXS) announced it will release its financial results for Q2 2020 on August 6, 2020, prior to the U.S. market opening. A conference call will follow at 10:00 a.m. ET to discuss the results and corporate developments. Investors can access the call via phone or webcast. Stereotaxis specializes in robotic technologies for treating cardiac arrhythmias, and its systems are approved in several major markets including the U.S., EU, and Japan.

STEREOTAXIS (NYSE: STXS), a leader in robotic technologies for cardiac arrhythmias, announced a publication in the European Heart Journal showcasing its technology's effectiveness in treating a COVID-19 patient with ventricular tachycardia. The publication advocates for remote catheter ablation to reduce infection risks for healthcare staff. The case study involved a 68-year-old patient who recovered without recurrence of arrhythmia. CEO David Fischel emphasized the technology's safety and efficiency in complex procedures, highlighting its role in protecting medical professionals during the COVID-19 pandemic.

Stereotaxis (NYSE: STXS) announced its inclusion in the Russell 2000® and Russell 3000® Indexes, effective after the market closes on June 26, 2020. This addition is part of the annual reconstitution of the Russell Indexes, which are relied upon by institutional investors for their integrity. David Fischel, Chairman and CEO, expressed excitement about this milestone, viewing it as a significant step to enhance awareness of the company's innovative cardiac technologies. Stereotaxis specializes in robotic systems for the treatment of arrhythmias and endovascular procedures.

Stereotaxis (NYSE: STXS) announced that Chairman and CEO David Fischel will present at the Cowen 5th Annual FutureHealth Conference on June 25, 2020, at 10:15 am EDT. Fischel will lead a panel titled The Powerful Combination of Advanced Imaging & Robotics, discussing the integration of advanced diagnostic imaging with robotic technologies to enhance patient care. Highlights include Stereotaxis' collaboration with Acutus Medical in cardiac mapping and its efforts in digitizing interventional surgery.

Stereotaxis (NYSE: STXS) has announced an inaugural Symposium to be held on June 20, 2020, via live interactive webcast. The event will showcase bi-directional TeleRobotic procedures, enabling physicians to navigate catheters from over 1700 km apart. A panel discussion will follow, focusing on enhancing patient care, expanding therapy access, and improving physician education in TeleRobotic Surgery. Furthermore, the TeleRobotic Surgery Leadership Council has been formed to advance remote surgical support. Registration is open to healthcare professionals and industry partners.